To assess the effect of blue-light filtering (BLF) intraocular lenses (IOL) on the prevention of neovascular AMD (nAMD) following cataract surgery.
Cohort study.
Patients who underwent uneventful cataract surgery between 2007 and 2018 at the Ophthalmology Unit of Kymenlaakso Central Hospital, Finland.
Subsequent nAMD rates were compared between subjects who received BLF-IOL (SN60WF, Alcon Laboratories Inc.) or non-BLF-IOL (ZA9003 and ZCB00, Johnson & Johnson Vision, Inc.). Kaplan-Meier and Cox regression analyses for the overall risk of developing nAMD were assessed. Best-corrected visual acuity (BCVA), foveal thickness, treatment interval and the total number of intravitreal injections were secondary outcomes. A separate analysis was performed on patients with pre-existing nAMD to assess the effect of BLF-IOL on nAMD progression. A single eye of each patient was included.
nAMD free survival.
Included were 11,397 eyes of 11,397 patients with a mean age of 75.4±8.3 years (62.5% female). The BLF IOL was used in 5,425 eyes (47.6%) and the non-BLF IOL in 5,972 cases (52.4%). During follow-up (55.2±34.1 months for the BLF IOL and 50.5±30.1 months for the non-BLF IOL, p0.05).
In a large cohort of patients who underwent cataract surgery, the use of BLF-IOL resulted in no apparent advantage over a non-BLF-IOL in the incidence of nAMD or its progression, nor in clinical variables related to nAMD severity.

Copyright © 2020. Published by Elsevier Inc.